Navigation Links
Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention

CRANBURY, N.J., June 22, 2011 /PRNewswire/ -- The founders of Oncobiologics, Inc. today announced that the firm, a specialist in biologics proof-of-concept services, will launch itself to the biopharmaceutical industry at the 2011 BIO International Convention. The convention is being held June 27-30 at the Walter E. Washington Convention Center in Washington, DC.

Oncobiologics was founded by a group of leading scientists and engineers from top-tier global pharmaceutical and biotech companies, including Genentech, Eli Lilly, Bristol-Myers Squibb, Bayer, Merck, Johnson & Johnson, Schering-Plough and Medarex. The company is commercializing a new one-stop proof-of-concept "engine" that will enable biologic drug developers to economically and efficiently develop more of their pre-clinical drug candidates. Oncobiologics has raised start-up funding through U.S. government grants, bank loans, and investments by listed companies and private equity investors.

Oncobiologics founder and CEO Dr. Pankaj Mohan commented, "Oncobiologics was created to help unleash the tremendous wealth of pre-clinical assets generated by the U.S. biopharmaceutical industry. Historically, roughly 40% of those assets suffer significant delays due to capacity and financial constraints. Oncobiologics aims to deliver the world-class technical capabilities found at top-tier companies, with a cost structure that more closely resembles low-cost country outsourcing, thus easing this critical bottleneck."

Adds Mohan, "Our team sees a great business opportunity here, but we are equally committed to opening up the flow of promising drug candidates to the patient populations that so desperately need them."

The Oncobiologics business model features a core set of expert services that are supplemented by strategic partnerships with external industry specialists. Internal services include cell and molecular biology; and process, analytical and formulation development. Manufacturing services include stability studies; non-clinical manufacturing and QC testing, with clinical manufacturing commencing in 2012. Partner offerings include pre-clinical animal studies, immunogenicity studies, clinical study design and execution and regulatory affairs. Oncobiologics offers comprehensive turnkey proof-of-concept program outsourcing, or discrete projects to complement a client's internal development efforts.


Dr. Pankaj Mohan, Founder and CEO

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE Oncobiologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DNA Analyzer "Hello Truth" Unveiled During Innocence Network International Delegate Tour of DDC
2. Pharma ChemOutsourcing 2011 Unveils First Wave of 50 Biotech Chemist Speakers for September 12-15 Show in New Jersey
3. Shrink Nanotechnologies Unveils Product Image of Initial StemDisc450 Prototype
4. Cellectis Unveils Its New Corporate Website
5. Secrets of a chiral gold nanocluster unveiled
6. Lilly Oncology to Unveil More Than 50 Studies at ASCO 2010
7. iCyt Unveils New Flow Cytometry Products in Collaboration with Sony at CYTO2010
8. ClearTrial Unveils New Product Release at Partnerships in Clinical Trials Conference 2010
9. Johnson & Johnson Consumer Companies, Inc., Unveils CYTOMIMIC(TM) Technology at 68th Annual Meeting of the American Academy of Dermatology
10. Stem Cell Assurance Unveils Physician Network Offering Regenerative Cell Cosmetic and Reconstructive Applications
11. Brooks Instrument Unveils New Web site
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight Medical ... to the healthcare market. The company's primary focus is on new product introductions, ... strategies that are necessary to help companies efficiently bring their products to market. ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
Breaking Biology News(10 mins):